Clinical Trial Update: Pembrolizumab And Lenvatinib In Leptomeningeal Metastases [Phase 2]

View source ↗

Summary

This clinical trial update reports that the Phase 2 study of pembrolizumab and lenvatinib in leptomeningeal metastasis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis

Drugs mentioned

• LENVIMA (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Solid Tumor, Solid Tumor, Adult | Phase 2 | Status: TERMINATED